Can a Two-Drug antiviral combo boost survival in liver cancer patients?

NCT ID NCT07253220

Not yet recruiting Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two antiviral strategies—one using a single drug (TAF) and the other starting with two drugs (entecavir plus TAF) then switching to TAF alone—in 120 people with advanced hepatitis B-related liver cancer who are also receiving immunotherapy. The main goal is to see which approach leads to better survival at 24 months. Researchers will also track virus levels and liver function over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tenofovir alafenamide (TAF) and entecavir (ETV)
What this could lead to: If successful, this could show that combining two antivirals before switching to one helps people with hepatitis B-related liver cancer live longer during immunotherapy.
What could go wrong: This is a small, early-stage study with only 120 participants, so results may not apply to everyone. The trial hasn't started yet, and it's unclear if one strategy is truly better.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatitis B virus infection hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATITIS B HEPATOCELLULAR CARCINOMA (HCC)

More trials for these conditions

Other studies related to the condition(s) this trial covers.